SKYE · Skye Bioscience, Inc.

Skye Bioscience Inc Is A Pre-Clinical Pharmaceutical Company Located In San Diego, California. The Company'S Clinical Assets Focus On The Modulation Of Cannabinoid Receptor 1 ("Cb1") To Provide Novel Treatments And Alternatives For Diseases Caused By Metabolic Disorders, Inflammation, Fibrosis, And Neurodegeneration, Such As Obesity And Glaucoma. The Company'S Phase 2 Clinical Candidates Include Nimacimab, A Negative Allosteric Modulating Antibody That Inhibits Peripheral Cb1 Receptors, Currently Being Developed For The Treatment Of Obesity And Sbi-100 Ophthalmic Emulsion ("Sbi-100 Oe"), A Cb1 Agonist (Activator), Currently Being Developed For The Treatment Of Glaucoma And Ocular Hypertension.